April 10, 2020. NCHR signed on to this letter to express our grave and urgent concern for the independence of federal inspectors general.
Read More »Author: Caroline Bradford
NCHR Comment on FDA’s Draft Guidance to Industry on Establishing Effectiveness and Safety for Hormonal Drug Products Intended to Prevent Pregnancy
September 10, 2019: In response to FDA’s request for public comments, we stated that the agency should require better testing of hormonal birth control pills and patches. Current studies don’t include enough women with higher BMIs or track blood clot risks properly. Our comments push for stronger safety standards that test hormonal contraceptives on women of all weights, especially since some birth control methods may be less effective or more dangerous for larger women.
Read More »FDA Ending Controversial ‘Alternative Summary Reporting’ Program
DOTMed News: May 8, 2019. The FDA’s alternative summary reporting system hid information about patients who were harmed by medical devices. FDA says it will stop this cover-up and require reporting of each patient harmed by a device.
Read More »Drug Campaign Touts ‘Female Viagra’ in the Name of Equality
Kaiser Health News: May 8, 2019. The “female viagra” pill was not shown to be effective before it was approved by the FDA, or since. But it does have risks. It is not a feminist dream come true.
Read More »FDA Will Not Ban Textured Breast Implants at this Time
NBC News: May 3, 2019. After years of reports of safety concerns regarding textured breast implants, they will not be removed from the market, says FDA.
Read More »